Novartis Share Price

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis AG, the world’s second largest pharmaceutical company. The company is involved in the pharmaceutical business in India, offering therapeutic products in the areas of bone and pain, transplantation immunology, and neuroscience. The Novartis India share price today on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries.

Market sentiment around the Novartis India stock price often mirrors shifts in healthcare spending, regulatory policies on drug pricing, and investor views on the pharmaceutical sector’s growth prospects. Factors such as the pace of new product launches, competitive intensity from domestic and multinational players, regulatory changes from the CDSCO, and government policies on healthcare influence near-term market valuation and medium-term earnings forecasts. All these factors must be closely monitored to have an idea about the Novartis India stock price movements.

Novartis India live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant monitoring of Novartis India live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market.

Furthermore, monitoring the Novartis India price helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook.

Novartis India Limited Company Fundamentals

a. Company Background

Novartis India Limited was incorporated in 1947. The company’s registered office is located in Mumbai, India. The company was originally incorporated on December 13, 1947, under the name Ciba Pharma Pvt. Ltd., as a wholly owned subsidiary of Ciba Ltd., Basle, Switzerland. The name of the Company was changed from Ciba Pharma Pvt. Ltd., to Ciba of India Ltd., with effect from January 5, 1961, soon after the amalgamation of Ciba Dyes Pvt. Ltd. The name was again changed to Ciba-Geigy of India Ltd., with effect from October 21, 1970, and to Hindustan Ciba-Geigy Ltd., with effect from January 1, 1983. In 1996, in one of the largest corporate mergers in history, Sandoz and Ciba-Geigy Ltd. joined to form Novartis. NIL’s primary activity involves manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare. It operates into four segments: Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. From purely trading activities, the Company moved to the manufacture of pharmaceutical formulations and later undertook the manufacture of a large number of bulk drugs. The company has played a pivotal role in bringing innovative medicines to India, including the launch of Glivec. Over the years, NIL has significantly expanded its product portfolio and market presence. It operates in a regulated environment, with pricing and marketing governed by the National Pharmaceutical Pricing Authority (NPPA) and the Central Drugs Standard Control Organization (CDSCO). The company has consistently focused on enhancing its product offerings and healthcare access to meet the growing demand for quality medicines.

b. Product Lines

• Therapeutic products in the areas of bone and pain under the Voveran brand

• Transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands

• Neurosciences products under the Tegrital and Exelon brands

• Generics and over-the-counter (OTC) medicines

• Animal healthcare products

• Pharmaceutical formulations for consumer healthcare

c. Company Revenue Model

• Primary revenue from the sale of pharmaceutical products across four segments: Pharmaceuticals, Generics, OTC, and Animal Health

• Volume-driven revenue based on quantity of drugs sold to hospitals, pharmacies, and distributors

• Pricing determined by regulatory frameworks (NPPA) and competition, affecting overall revenue generation

• Revenue from prescription drugs as well as generic and OTC medicines

• Imports medicines from Novartis global units and distributes via its sales network and partners

• Focus on niche, high-barrier therapies: organ transplant, neurology, pain management

• Seasonal variations in demand for certain therapeutic categories affecting revenue patterns throughout the year

• Government policy changes on drug pricing and healthcare spending influencing revenue stability

d. Geographic Presence

• Strong presence across India with registered office and corporate headquarters in Mumbai, Maharashtra

• Manufacturing and research facilities located across multiple locations in India

• Novartis has designated its India operations as the company’s largest global corporate center outside Basel, employing over 9,000 people and representing 11% of the company’s worldwide workforce

• The company has a broad presence, including commercial pharma operations, drug development, biomedical research, and operations

• Global capability centre workforce is based in India, with nearly two-thirds of Novartis’ global capability centre workforce located in the country

• Novartis is significantly expanding its biomedical research and drug development operations in India, positioning it as a key global hub outside Switzerland

• Operations primarily concentrated in India, serving domestic markets across all states

e. Key Milestones

• 1947: Incorporated as Ciba Pharma Pvt. Ltd. on December 13

• 1961: Name changed to Ciba of India Ltd. on January 5

• 1970: Name changed to Ciba-Geigy of India Ltd. on October 21

• 1983: Name changed to Hindustan Ciba-Geigy Ltd. on January 1

• 1996: Novartis formed following merger of Sandoz and Ciba-Geigy

• 1998: Set up the Novartis Institute for Functional Genomics

• 2000: Acquired products Famvir and Vectavir/Denavir from SmithKline Beecham

• 2003: United generics businesses under Sandoz global brand; granted Exclusive Marketing Rights (EMR) for Glivec

• 2025: Novartis AG announced transfer of its 70.68% stake in Novartis India Limited to a group of private equity firms

f. Industry Perspective

Novartis India Limited operates in the pharmaceutical industry, which is a core component of India’s healthcare sector. Globally, the medicine market was valued at approximately USD 1.5 trillion in 2025 and is projected to grow at a CAGR of 3-6% through 2026, reaching close to USD 1.8 trillion. In India, the pharmaceutical industry is currently valued at USD 50 billion and is expected to reach USD 65 billion by 2024, and thereafter USD 120-130 billion by 2030. During FY18 to FY23, the Indian pharmaceutical industry logged a compound annual growth rate of 6-8%. The domestic formulations market is projected to grow at an 8-10% CAGR (reaching USD 20-22 billion in FY24), with export growth forecasted at 10% (reaching USD 22-24 billion). The government aims to increase healthcare spending and access, with the AB-PMJAY scheme receiving increased allocation. The Indian pharma industry currently contributes to approximately 1.5% of India’s GDP. Demand is driven by rising disease burden, increasing healthcare awareness, and government initiatives like Ayushman Bharat. Key challenges include regulatory compliance, increased competition, pricing pressures, and the upcoming Drugs, Medical Devices and Cosmetics Bill, 2023.

Novartis India Limited Stock Market Presence: Listings & Index Representation

Novartis India is actively traded on India’s principal equity markets, with its shares listed on the National Stock Exchange of India (NSE) under the symbol NOVARTIND and on the Bombay Stock Exchange (BSE) with the scrip code 500672. Its listing on both exchanges ensures that the Novartis India price is accessible to a wide investor base, encompassing both retail and institutional market participants. The company was listed on BSE on June 9, 2000, and on NSE on May 17, 1995. The company forms part of several benchmark indices that represent broad market segments. Novartis India is included in indices such as S&P BSE 500, S&P BSE AllCap, and S&P BSE SmallCap on the BSE. Being represented in multiple indices enhances the visibility and liquidity of the Novartis India stock price, as index tracking funds and exchange traded strategies often adjust allocations in line with constituent revisions. It also allows investors to benchmark the company’s stock performance relative to broader market trends and peer groups, facilitating cross sectional comparisons within India’s pharmaceutical landscape. The inclusion of Novartis India in these indices reflects its market capitalisation and trading depth, which are key factors market participants consider when evaluating long term investment prospects and the responsiveness of the stock price to corporate and industry developments.

Novartis India Limited Stock Performance and Share Price History

The Novartis India price has exhibited significant volatility over the past decade, shaped by the company’s position as a subsidiary of a global pharmaceutical giant and broader industry cycles. The Novartis India share price recorded a positive total return of approximately 25.58% over the last 1 year (as of April 9, 2026), outperforming the BSE Healthcare index which returned 2.5%. The Novartis India share price delivered a 5-year total return of 56.12% and a 10-year total return of 4.4%, demonstrating moderate long-term wealth creation despite recent volatility. The Novartis India share price reached a 52-week high of ₹1,099.90 and a 52-week low of ₹747.60, indicating a wide trading range and substantial price fluctuations of approximately ₹352 from peak to trough. The Novartis India share price recorded a strong rally in 2024, while the subsequent period has seen the Novartis India stock price consolidate near its highs. The Novartis India share price has shown a 1-month return of approximately 7.6% and a 3-month return of 27.5% as of April 2026, indicating positive momentum.

The Novartis India stock price has been particularly responsive to quarterly earnings releases and corporate announcements. When the company reported a 99.59% rise in net profit in the March 2025 quarter, the Novartis India stock price showed a positive reaction. The Novartis India share price has shown a pattern of positive momentum in years when the company’s earnings exceeded expectations, while periods of earnings moderation or concerns over parent company strategic decisions have contributed to consolidation in the Novartis India stock price. Corporate developments, including strategic announcements such as the proposed divestment of Novartis AG’s 70.68% stake in the company to private equity firms, have also influenced short-term fluctuations in the Novartis India share price. The Novartis India share price has shown a 3-year total return of 31.74% and a 5-year total return of 56.12%. The Novartis India share price reached its 52-week high of ₹1,099.90 before declining to its 52-week low of ₹747.60, reflecting the volatility inherent in the pharmaceutical space. The Novartis India share price has shown a year-to-date return of 28.4% as of April 2026, indicating continued positive momentum in the current fiscal year. Comprehending these patterns in the Novartis India share price is instrumental for investors seeking to contextualise long term performance trends vis à vis short term price dynamics, as the Novartis India price movements illustrate how industry fundamentals, regulatory policy cycles, and investor expectations converge in market pricing.

The Novartis India share price has shown distinct seasonal patterns over the past decade. In terms of annual performance, the Novartis India share price delivered its strongest annual return of 18.6% in 2024, followed by a positive return of 14.6% in 2023, 12.5% in 2021, and 2.2% in 2020. The stock recorded negative annual returns in 2025 (-14.6%), 2022 (-12.9%), and 2019 (-8.0%). The Novartis India share price has demonstrated that the stock tends to perform better in periods of strong pharmaceutical demand and favourable regulatory environment, while underperforming during phases of pricing pressure and intense competition.

Novartis India Limited Investor Relevance and Role in Portfolio

Novartis India holds a significant position for portfolio investors who seek exposure to India’s pharmaceutical sector with a focus on multinational pharmaceutical companies. The company’s diversified product portfolio across prescription drugs, generics, OTC medicines, and animal health, along with its association with global parent Novartis AG, aligns it with investment strategies that value global R&D backing and established brand equity. The Novartis India price often mirrors how these themes resonate with investor portfolios, whereby both thematic and sector specific funds monitor regulatory approvals, drug pricing trends, and healthcare spending indicators when evaluating allocation decisions.

Institutional stakeholders play a significant role in Novartis India’s ownership profile, with notable long term investment entities such as Novartis AG (promoter holding 70.68%), Atul Limited (1.52%), Investor Education and Protection Fund (IEPF) (0.69%), and Dimensional Fund Advisors LP among key shareholders identified in institutional holdings data. Mutual fund holders of Novartis India include mutual funds as per shareholding data. As of December 2025, promoters held 70.68%, Mutual Funds held 0.00%, Insurance companies held 0.51%, Foreign Institutional Investors (FIIs) held 0.19%, Domestic Institutional Investors (DIIs) held 0.12%, and Retail held 28.51%. Institutional investors hold 0.82% of NOVARTIS as of December 2025. These investors represent a blend of domestic and international perspectives that contribute to the stock’s market liquidity and visibility within broader investment frameworks.

The beta analysis of Novartis India across multiple time periods highlights its changing volatility in relation to the overall market. Based on data, the 5-year monthly beta stands at 0.31, indicating that the stock is significantly less volatile than the broader market over an extended period. In short-term analysis, the 1-year beta is 0.50, showing low sensitivity to market fluctuations. Based on data from TradingView, the beta coefficient is 0.81, with stock volatility of 2.35%. Based on data from Simply Wall St, the beta is -0.059, indicating an inverse relationship with the market. The stock’s price volatility is approximately 2.35% according to recent data. The average weekly movement of Novartis India stock is approximately 2.5-3%, compared to the pharmaceutical industry average of 4-5% and the market average of 5-6%, indicating lower volatility than both its industry and the broader market. The Novartis India share price has shown periods of heightened responsiveness to sector-specific news and quarterly earnings releases. The Novartis India stock price’s beta reflects that the company’s established brand presence and association with a global parent may provide some stability, though the pharmaceutical sector remains sensitive to regulatory changes and drug price fluctuations.

Novartis India Limited Sectoral Relevance and Peer Positioning

The sector relevance of Novartis India is anchored in its role within the broader Indian pharmaceutical industry, where it competes with other diversified drug manufacturing companies. As part of this industry, the company’s strategic positioning connects innovative medicines, generics, and consumer health products that serve multiple healthcare needs. Competitors in the pharmaceutical segment include companies such as Sun Pharmaceutical Industries Limited, Cipla Limited, Abbott India Limited, Sanofi India Limited, Dr. Reddy’s Laboratories Limited, Lupin Limited, Aurobindo Pharma Limited, Torrent Pharmaceuticals Limited, and Zydus Lifesciences Limited. Firms with parallels in either multinational parentage or therapeutic focus are often referenced when evaluating relative performance and operational positioning within the sector.

In valuation terms, factors like the Novartis India P/E ratio have shown variations over different periods. The mean historical P/E ratio over the last ten years has varied, with the current 19.20 P/E ratio having changed -55% with respect to the historical average. Periods when investors perceived improvements in profitability or earnings sustainability have corresponded with expansion in valuation multiples, whereas phases of moderation in earnings momentum or industry cyclicality have seen valuation contraction. The Novartis India P/E ratio decreased in 2025 (to 19.20, -55%), 2023 (to 65.20, +383%), and 2024 (to 32.70, -49.8%), and increased in 2022 (to 13.50, -58.7%). The P/E ratio was at its highest in 2023 at 123x and at its lowest in 2022 at 13.50x.

Similarly, the Novartis India EPS narrative has shown variation according to how operational performance aligns with industry demand cycles and cost structures. Structural gains from cost optimization and focus on high-margin therapies supported directional improvement in earnings per share during favourable conditions, while cyclical headwinds from pricing pressures and regulatory changes have moderated EPS momentum. Novartis India earnings have shown a trajectory that responded to both revenue growth and margin pressures over the analysed period. Novartis India market cap has fluctuated in line with investor perceptions of the company’s growth potential in a competitive and rapidly evolving pharmaceutical market.

Over the last ten years, the market capitalisation of Novartis India has followed a pattern of growth followed by moderation. From fiscal year 2016 onwards, the company’s market cap showed an increasing trend, reflecting strong investor confidence. The market cap increased from ₹16,933 million in 2019 to ₹12,401 million in 2020, ₹13,629 million in 2021, ₹14,579 million in 2022, ₹13,958 million in 2023, and reached a peak of ₹25,396 million in 2024. This represents a total increase of 50% from 2019 levels. The current market cap stands at approximately ₹2,151-2,469 crore as of April 2026. This increase mirrors the appreciation in the Novartis India share price and the broader performance of the pharmaceutical sector.

The earnings history of Novartis India over the past ten years has been characterised by a period of volatility followed by strong recovery. Net income showed a generally increasing trend in recent years, with reported net profit rising from ₹20.9 crore in 2021 to a loss of ₹3.72 crore in 2022, before a strong recovery to ₹103.36 crore in 2023, ₹85.19 crore in 2024, and ₹100.90 crore in 2025. Revenue has been choppy, declining from ₹438 crore in 2021 to ₹335 crore in 2025, a negative compound annual growth rate. For the nine months ended December 31, 2024, the business recorded 2.54 billion rupees in operational revenues, down from 3.03 billion rupees during the same period in 2022. This recent earnings improvement reflects the impact of cost optimization, focus on high-margin therapies, and operational efficiency on the company’s profitability.

The Earnings Per Share (EPS) history for Novartis India has shown significant variation over the past decade. The diluted EPS growth rate has shown variation, with EPS at ₹41.88 in Mar2024, -₹1.51 in Mar2023, ₹8.47 in Mar2022, and ₹4.08 in Mar2021. Over a ten-year period, the company demonstrated mixed EPS performance, with average earnings per share growth in recent years. In recent years, EPS showed a pattern of recovery from negative territory to positive levels. The current TTM EPS stands at approximately ₹39.38 to ₹41.63. The highest EPS growth was recorded in the 2023-2024 period as the company returned to strong profitability.

The Price-to-Earnings (P/E) ratio history of Novartis India has shown fluctuations over the ten-year period. At the end of recent fiscal years, the P/E ratio varied, with 2025 at 19.20, 2024 at 32.70, 2023 at 65.20, 2022 at 13.50, and 2021 at 29.80. The mean historical P/E ratio over the last ten years has varied significantly. The current P/E ratio stands at a discount to the industry peer median of 53.44 times, reflecting that investor expectations are adjusting to near-term earnings headwinds. The Novartis India share price has been influenced by these valuation metrics. The Novartis India stock price continues to be evaluated in the context of its earnings potential and market position.

Summary

Novartis India is a prominent pharmaceutical company in India listed on both the NSE and BSE, where the Novartis India share price reflects healthcare spending cycles, drug pricing regulations, and product portfolio expansion within the pharmaceutical sector. Its representation in multiple stock indices supports market visibility, while investor interest is shaped by earnings trends, valuation narratives, and broader healthcare access themes. Within the sector, the company’s competitive context and earnings dynamics provide key perspectives on its role in India’s pharmaceutical market.